The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

• Status: Completed
• Trial end date: 2017-12-10
• Target enrollment: 0
• Participant gender: All

Summary

Delineation of the role of glucagon-like peptide-1 receptor signalling in the glucose-lowering effect of metformin during meal ingestion in patients with type 2 diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Gentofte, Copenhagen
• Collaborator: University of Copenhagen
• Treatments: Glucagon; Glucagon-Like Peptide 1; Metformin

Criteria

Inclusion Criteria:

• Type 2 diabetes for at least three months (diagnosed according to the criteria of the World Health Organization (WHO)), with a HbA1c <58 mmol/mol.

• Caucasian ethnicity

• Lifestyle intervention and/or metformin monotherapy

• Normal haemoglobin

• Age >18 years

• BMI >23 kg/m2 and <35 kg/m2

• Informed and written consent

Exclusion Criteria:

• Liver disease

• Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery

• Hypo- or hyperphosphataemia

• Reduced kidney function or nephropathy

• Treatment with medicine that cannot be paused for 12 hours

• Intake of antibiotics two months prior to study

• Hypo- or hypercalcaemia

• Hypo- and hyperthyroidism

• Treatment with oral anticoagulants

• Active or recent malignant disease

• Any treatment or condition requiring acute or sub-acute medical or surgical intervention

• Lack of effective birth control in premenopausal women

• Positive pregnancy test on study days in premenopausal women

• Pregnancy

• Women who are breastfeeding

• Any condition considered incompatible with participation by the investigators

• If the subjects receive any antibiotic treatment while included in the study they will be excluded